Myriad Genetics (NASDAQ:MYGN – Get Free Report) updated its fourth quarter 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.030-0.040 for the period, compared to the consensus EPS estimate of 0.030. The company issued revenue guidance of $209.0 million-$211.0 million, compared to the consensus revenue estimate of $212.8 million. Myriad Genetics also […]